Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study by Primavera, Diego et al.
 1Primavera D, et al. BMJ Open 2017;7:e014938. doi:10.1136/bmjopen-2016-014938
Open Access 
AbstrAct
Introduction Brain-derived neurotrophic factor (BDNF) 
plays a crucial role in neurodevelopment, synaptic plasticity 
and neuronal function and survival. Serum and plasma 
BDNF levels are moderately, but consistently, decreased 
in patients with schizophrenia (SCZ) compared with 
healthy controls. There is a lack of knowledge, however, 
on the temporal manifestation of this decline. Clinical, 
illness course and treatment factors might influence the 
variation of BDNF serum levels in patients with psychosis. 
In this context, we propose a longitudinal study of a cohort 
of SCZ and schizophrenic and schizoaffective disorder 
(SAD) Sardinian patients with the aim of disentangling the 
relationship between peripheral BDNF serum levels and 
changes of psychopathology, cognition and drug treatments.
Methods and analysis Longitudinal assessment 
of BDNF in Sardinian psychotic patients (LABSP) is 
a 24-month observational prospective cohort study. 
Patients with SAD will be recruited at the Psychiatry 
Research Unit of the Department of Medical Science 
and Public Health, University of Cagliari and University 
of Cagliari Health Agency, Cagliari, Italy. We will collect 
BDNF serum levels as well as sociodemographic, 
psychopathological and neurocognitive measures. 
Structured, semistructured and self-rating assessment 
tools, such as the Positive and Negative Syndrome 
Scale for psychopathological measures and the Brief 
Assessment of Cognition in Schizophrenia for cognitive 
function, will be used.
Ethics and dissemination This study protocol was 
approved by the University of Cagliari Health Agency Ethics 
Committee (NP2016/5491). The study will be conducted 
in accordance with the principles of good clinical practice, 
in the Declaration of Helsinki in compliance with the 
regulations. Participation will be voluntary and written 
informed consent will be obtained for each participant 
upon entry into the study. We plan to disseminate the 
results of our study through conference presentations and 
publication in international peer-reviewed journals. Access 
to raw data will be available in anonymised form upon 
request to the corresponding author.
IntroductIon
Brain-derived neurotrophic factor (BDNF) 
is the most widely distributed neurotrophin 
in the central nervous system (CNS),1 being 
expressed in almost all the cortical areas, as 
well as in several spinal cord regions.2 There is 
substantial evidence that BDNF plays a crucial 
role during brain development, as well as in 
the process of differentiation, synaptogen-
esis and neuronal plasticity.3–6 BDNF was the 
second neurotrophic factor to be character-
ised after the nerve growth factor.7 Similar to 
other neurotrophins, BDNF is synthesised in 
a pre–pro form consisting of 47 amino acids.2 
Extracellular BDNF appears to have two 
forms: pro-BDNF and mature BDNF,2 8 which 
are formed after cleavage of the precursor 
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Protocol
Strengths and limitations of this study
 ► This is a prospective cohort study of patients with 
psychosis aiming to clarify whether longitudinal 
changes in brain-derived neurotrophic factor (BDNF) 
serum levels are correlated with psychopathological, 
cognitive, and treatment factors.
 ► The secondary outcomes of this study will offer 
insight on the impact of psychiatric comorbidities 
on longitudinal trajectory of BDNF in patients with 
psychosis.
 ► Sampling will be performed in a tertiary clinic 
specialised in treatment of patients with psychosis, 
possibly limiting the ecological validity of the study 
results.
 ► The sample size, based on previous work on 
longitudinal change of BDNF over time, might 
not achieve sufficient statistical power to detect 
association signals with small effect sizes between 
clinical predictors and BDNF levels.
 ► Notwithstanding the prospective design, clinical 
(illness duration, duration of untreated psychosis) 
and treatment history prior to study entry might 
impact on findings.
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protein pre–pro-BDNF.8 9 Mature BDNF interacts with 
its high-affinity receptor, the tropomyosin-related kinase 
receptor type B (TRKB), to exert its molecular effects in 
the adult CNS.2 BDNF induces dimerisation of TRKB with 
kinase activation and autophosphorylation of tyrosine 
residues, with subsequent activation of several adaptor 
proteins, which, in turn leads to phosphorylation of phos-
phoinositide 3-kinase, mitogen-activated protein kinase/
extracellular signal-regulated kinase, phospholipase Cγ1 
and cyclic adenosine monophosphate (cAMP)-respon-
sive element-binding protein, all downstream pathways 
regulating neurite outgrowth, cell survival, cellular differ-
entiation and synaptic plasticity.2 10 There is evidence that 
the cleaved prodomain of BDNF might be, by itself, an 
active biological modulator.11 12 BDNF and its cleaved 
propeptide have been found in large vesicles located in the 
presynaptic terminals of excitatory neurons in the adult 
hippocampus of mice.11 Interestingly, the Val66Met poly-
morphism of BDNF, which is located in the prodomain 
genomic region, alters substantially the prodomain struc-
ture.12 Specifically, Met66 BDNF prodomain induces 
modulation of neuronal morphology through acute cone 
retraction.12
It is known that BDNF freely crosses the blood–brain 
barrier.13 In keeping with this observation, levels of BDNF 
in serum are correlated with CNS concentrations.14 
Altered peripheral serum levels of BDNF have been 
shown to be a reliable biomarker for severe psychiatric 
disorders, including schizophrenia (SCZ).15 This corre-
sponds to the dysregulation of BDNF and of its related 
molecular pathways observed in affected individuals.16
A decline in serum BDNF levels has been consistently 
identified in chronic and medicated SCZ patients,17–22 
as well as in first-episode and medication-naive 
SCZ patients,23–27compared with unaffected subjects. 
Conversely, other studies showed increased BDNF serum 
levels in patients with SCZ,28 29 or have not been able to 
demonstrate differences in serum BDNF concentrations 
between drug-free or drug-naive patients and healthy 
controls.30 31 This discrepancy may depend on the clin-
ical heterogeneity of the samples studied (ie, different 
stage of illness, subtype of SCZ and effect of medication), 
as well as on the different assessment tools employed. 
However, a recent quantitative meta-analytical estimate 
by Fernandes et al32 confirmed that SCZ is associated 
with a moderate decrease of serum and plasma BDNF 
levels compared with healthy controls. This entails that 
decreased serum BDNF levels might be a marker of illness 
status in SCZ (ie, disease biomarker). There is a lack of 
knowledge, however, on the temporal manifestation of 
this decline. The decrease of peripheral BDNF could be 
constant, with premorbid levels roughly similar to those 
detected in unaffected individuals, linearly declining 
during the course of SCZ. Alternatively, BDNF peripheral 
levels might fluctuate in association with acute psycho-
pathological phases of the disorder. On top of this, BDNF 
peripheral levels might vary as a result of drug treatments 
typically used in major psychoses, such as antipsychotics. 
To date, however, the study of the relationship between 
BDNF serum levels and drug treatment in patients with 
SCZ and schizoaffective disorder (SAD) remains incon-
clusive. There is extensive preclinical evidence suggesting 
that typical antipsychotics might decrease BDNF expres-
sion whereas atypical antipsychotics, with the exception of 
risperidone, could increase BDNF expression.33 Clozap-
ine-treated patients with chronic SCZ have higher BDNF 
levels than patients treated with typical neuroleptics18 20 
or with risperidone.18 Other studies, however, found no 
effect of antipsychotic treatment on the levels of serum 
BDNF.25 34 35 Taken together, these data appear contra-
dictory, making difficult to infer conclusions about the 
effects of antipsychotic treatment on serum BDNF levels. 
Meta-analytical findings, however, point to a small but 
significant increase of serum BDNF levels under antipsy-
chotic treatment, although a class-specific effect has not 
been investigated.32
One final introductory remark concerns the link 
between BDNF and cognitive function in SCZ. Indeed, 
cognitive disruption seems to represent the core symp-
tomatology that distinguishes patients with SCZ from 
those affected by other psychoses. Cognitive deficits are 
related to social integration, to social problem solving 
and to the acquisition of various skills36 and are consid-
ered the most powerful predictors of functional outcome 
in patients with SCZ.37 Cognitively impaired patients with 
chronic SCZ appear to show low-serum BDNF levels.38 
A recent meta-analysis confirmed this observation,39 
showing that higher levels of BDNF peripheral expres-
sion correlated with better cognitive performances in 
reasoning and problem-solving areas.
The apparent gap in the knowledge about the longitu-
dinal variation of BDNF serum levels, and its relationship 
with clinical and treatment variables in major psychoses, 
needs to be filled by additional clinical research. Here, 
we present the design and methodology of a prospective 
observational study that takes advantage of a well-char-
acterised population of patients with psychosis carefully 
monitored at an academic community health centre.
Aims of the current study
Our study has the following primary and secondary aims:
Primary aims:
1. Explore the longitudinal relationship between 
peripheral serum BDNF levels and variation in 
psychopathology in a cohort of patients with major 
psychosis recruited at different stages of the illness.
2. Assess whether variation of cognitive function 
correlates with peripheral BDNF serum levels.
3. Establish whether drug treatment impacts on 
the relationship between psychopathology and 
cognition with BDNF serum levels.
Secondary aims:
1. Study whether patients’ baseline characteristics 
prior to enrolment, namely duration of illness, 
duration of untreated psychosis (DUP), psychiatric 
and somatic comorbidity, age at onset, gender, 
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family history of psychiatric disorders, premorbid 
adjustment and the type of illness course, might 
moderate the longitudinal relationship between 
peripheral serum BDNF and psychopathology.
2. Study whether measures of peripheral serum BDNF 
levels correlate with baseline measure of social 
functioning.
3. Analyse the relationship of peripheral BDNF 
levels with tolerability of antipsychotic treatment, 
as expressed by the presence of extrapyramidal 
symptoms (EPS).
Methods
study design
Longitudinal assessment of BDNF in Sardinian psychotic 
patients (LABSP) is a 24-month observational prospective 
cohort study. The sample will be recruited from patients 
followed up and treated at the community mental health 
centre of the Psychiatry Research Unit of the Depart-
ment of Medical Science and Public Health, University 
of Cagliari and University of Cagliari Health Agency, 
Cagliari, Italy. Blood samples from recruited patients will 
be taken at baseline (T0) and at three consecutive time 
points: 6 months (T1), 12 months (T2) and 18 months (T3) 
(figure 1). The temporal fluctuations of psychopathology, 
as well as the assessment of pharmacotherapy, measures 
of cognitive function and manifestation of treatment-re-
lated side effects (ie, EPS), will be also evaluated at each 
time point (table 1). The observational prospective 
design permits to disentangle how each variable might 
influence the outcome under study. Thus, we will assess 
whether changes in peripheral serum levels of BDNF 
predate or, alternatively, are consequent to  psychopatho-
logical changes and/or drug treatment. As we will study 
the trajectory of peripheral serum BDNF levels over time, 
the recruited cohort will serve as its own control. We also 
expect to obtain an accurate estimation of the patterns of 
association between BDNF serum levels and all the inde-
pendent clinical variables under consideration.
Participants and recruitment
The recruitment of the sample will be based on a two-step 
process. In the first step, all patients followed up at 
the community mental health centre of the University 
of Cagliari Health Agency, Cagliari, Italy with a diag-
nosis of SCZ or SAD according to the Diagnostic and 
Statistical Manual of Mental Disorders-IV-Text Revision 
(DSM-IV-TR)40 will be identified in the medical record 
database. The electronic search will be performed using 
lower (18) and upper (65) age limits, with no constraint 
regarding the presence of comorbid psychiatric disor-
ders. After eligible patients will be identified in the 
database, the diagnosis of SCZ or SAD will be confirmed 
using the Structured Clinical Interview for DSM-IV-TR 
Axis I Disorders, Patient Edition (SCID-I/P)41 adminis-
tered by trained mental health professionals (psychiatry 
residents or senior clinical staff). Further, we will collect 
detailed information on pharmacological treatment 
regime. Given the characteristics of the patient popula-
tion followed up at our community mental health centre, 
we anticipate that our sample will not be comprised of 
drug-naive patients and will be on a pharmacological 
treatment regime mainly based on antipsychotics.
Inclusion and exclusion criteria
Inclusion criteria are: (1) age between 18 and 65 years; 
(2) diagnosis of SCZ or SAD according to DSM-IV-TR 
and (3) stability during the 6 months before recruitment. 
Exclusion criteria are: (1) refusal to provide consent; 
(2) presence of acute psychopathological symptoms; (3) 
presence of illness-related cognitive impairment of such 
severity that affects their ability to cooperate; (4) pres-
ence of major unstable medical illness; (5) severe mental 
retardation; (6) major neurological disorder or previous 
head injury; (7) current drug and alcohol dependence.
sample size and power calculation
Our main null hypotheses are that there is no difference 
between mean BDNF serum levels at different time points 
in relation to: (1) the longitudinal psychopathological 
changes of patients with SCZ and SAD; (2) measures of 
cognitive functioning and (3) drug treatment. We based 
our power analysis on previous findings of BDNF serum 
levels longitudinal variation in a small cohort (n=21) of 
patients with first-episode SCZ.24 Specifically, Palomino 
et al performed a 1-year prospective assessment of BDNF 
finding an absolute mean difference between baseline 
and the last time point of 1.65.24 Thus, a sample size of 59 
Figure 1 Flowchart of recruitment and assessment procedures for the Longitudinal assessment of BDNF in Sardinian 
psychotic patients study. BDNF, brain-derived neurotrophic factor; DSM-IV-TR, Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision; QOL, quality of life; SAD, schizoaffective disorder; SCZ, schizophrenia.
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individuals would be sufficient to obtain a 90% statistical 
power to detect significant difference at α=0.05 between 
mean serum BDNF levels of this magnitude at each time 
point, considering an attrition rate for time point of 
5%. Power analysis has been performed using repeated 
measures and sample size (RMASS) software.42
Table 1 Assessment protocol in the LABSP
Time points
Measure T0 (enrolment) T1 (6 months) T2 (12 months) T3 (18 months) T4 (24 months)
BDNF serum levels ✓ ✓ ✓ ✓ ✓
Descriptive variables
  Demographic data ✓
  Socioeconomic data ✓
  Clinical history ✓
  Family history ✓
Psychopathology
  SCID-I/P ✓
  SCID-II ✓
  PANSS ✓ ✓ ✓ ✓ ✓
  CGI-SCH ✓ ✓ ✓ ✓ ✓
  POLTQ ✓
  PAS ✓ ✓ ✓ ✓ ✓
Social functioning and quality of life
  PSP ✓ ✓ ✓ ✓ ✓
  SWN-S ✓ ✓ ✓ ✓ ✓
  WHOQOL-Bref ✓ ✓ ✓ ✓ ✓
Cognition
  BACS ✓ ✓ ✓ ✓ ✓
Assessment of side effects
  DOTES ✓ ✓ ✓ ✓ ✓
  ESRS ✓ ✓ ✓ ✓ ✓
Biometric, metabolic and cardiovascular measures
  Lipid profile ✓ ✓
  Kidney panel ✓ ✓
  Liver panel ✓ ✓
  Electrolytes ✓ ✓
  Weight, height, waist circumference, BMI ✓ ✓ ✓ ✓ ✓
  Glucose ✓ ✓
  Glycosylated haemoglobin ✓ ✓
  PRL ✓ ✓
  CPK ✓ ✓
  ECG ✓ ✓
BACS, Brief Assessment of Cognition in Schizophrenia; BDNF, brain-derived neurotrophic factor; BMI, body mass index; CGI-SCH, Clinical 
Global Impression Scale for Schizophrenia; CPK, creatine phosphokinase; DOTES, Dosage Record Treatment Emergent Symptom Scale; 
ESRS, Extrapyramidal Symptom Rating Scale; LABSP,  Longitudinal assessment of BDNF in Sardinian psychotic patients; PANSS, Positive 
and Negative Syndrome Scale; PAS, Premorbid Adjustment Scale; POLTQ, Psychopathological Onset Latency and Treatment Questionnaire; 
PRL, prolactin; PSP, Personal and Social Performance Scale; SCID-II, Structured Clinical Interview for DSM IV Axis II Disorders; SCID-I/P, 
Structured Clinical Interview for DSM IV Axis I Disorders; SWN-S, Subjective Well-Being under Neuroleptics-Short Version; WHOQOL-Bref, 
WHO Quality of Life—Bref.
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Measures and materials
Sociodemographic variables, personal and family history data
Sociodemographic data will be collected using the Associ-
ation for Methodology and Documentation in Psychiatry 
(AMDP)43 assessment tool. Briefly, we will gather infor-
mation on gender, age, level of education, marital status, 
offspring, economic status and occupation. Further, we 
will collect data on previous and current substance and/
or alcohol abuse and smoking status. The latter will be 
quantified also as number of cigarettes smoked per day. 
Information on family history of any psychiatric disorders 
will be collected through direct interview of the partic-
ipant and at least one first-degree relative or significant 
other, as well as through an accurate review of avail-
able medical records. We will gather information on 
the stage of menstrual cycle whenever available. Finally, 
the systematic review of clinical records will allow us to 
retrospectively collect data on the presence of a previous 
history of stressful life events (SLE), including childhood 
maltreatment. We will also monitor longitudinally the 
eventual manifestation of SLE.
Psychopathological measures
The main psychopathological measures will be collected 
through the AMDP syndrome scale,43 which has shown 
to be valid in discriminating various forms of psychoses, 
as well as in providing a detailed psychopathological 
description of the subjects under study.44 As previously 
reported, patients’ diagnosis will be confirmed using the 
Structured Clinical Interview (SCID)-I/P.41 Furthermore, 
all recruited patients will undergo assessment with the 
SCID for DSM-IV Axis II Personality Disorders (SCID-II)45 
to detect the presence of comorbid personality disorders. 
Information on age of onset, age at first intervention 
(pharmacological and/or psychotherapeutic and/or 
psychosocial) will be based on retrospective information 
collected through direct interview of the patient, and at 
least one relative or significant other, as well as through 
an accurate review of available medical records. This 
approach should minimise the impact of recall bias on 
the assessment of key clinical measures.
We will also estimate DUP, the interval between the age 
of onset of full-blown psychotic symptoms and first anti-
psychotic treatment, using the Psychopathological Onset 
Latency and Treatment Questionnaire.46 Indeed a longer 
DUP appears to be related to a worse short-term47 and 
long-term clinical outcome48 49 in SCZ individuals, as well 
as with lower BDNF serum levels,50 although the latter 
finding has been not replicated in subsequent studies.51 
Other measures of illness severity, such as number of 
hospital admissions and type of clinical course will be 
collected for the analysis.
Psychopathological assessment will include the Positive 
and Negative Symptom Scale for schizophrenia52 and the 
Clinical Global Impression Scale for Schizophrenia.53 
The latter measure is a valid assessment tool for moni-
toring longitudinal psychopathological symptoms in 
routine clinical practice.54 Moreover, we will assess 
premorbid dysfunction, a well established prognostic 
marker in patients with SCZ, using the Premorbid Adjust-
ment Scale.55 All these psychopathological measures will 
be analysed in relation to BDNF serum levels.
Social functioning and quality of life measures
Evaluation of social functioning will be carried out with 
the Personal and Social Performance Scale,56 which 
showed good reliability in patients with SCZ.57 Further, 
assessment of quality of life (QOL) will be performed 
using the WHO Quality of Life—BREF (WHOQOL) 
version which has shown good validity and reliability in 
variety of psychiatric illnesses including SCZ.58 59 Finally, 
we will collect data using the Subjective Well-Being under 
Neuroleptics-Short Version.60
Cognitive measures
The cognitive performance will be examined in a stan-
dardised way using the Brief Assessment of Cognition in 
Schizophrenia Scale (BACS).61 It takes approximately 
half an hour to administer in healthy controls and 
includes brief assessments of four of the seven neuro-
cognitive domains designated as important by the 
Measurement and Treatment Research to Improve Cogni-
tion in Schizophrenia battery: reasoning and problem 
solving, processing speed, verbal memory and working 
memory. The composite score has been shown to have 
high test–retest reliability in patients with SCZ.61 More-
over, the BACS appears to assess reliable measures of 
functional capacity.62 The BACS will permit a rapid 
assessment of cognitive function at different time points, 
allowing correlation of these measures with peripheral 
serum BDNF levels. Indeed, several studies have shown 
that peripheral serum BDNF level might be a biomarker 
of cognitive function in SCZ.63–66
Assessment of side effects
We will monitor the onset of antipsychotics-related side 
effects using the Dosage Record  Treatment Emergent 
Symptoms Scale67 and the Extrapyramidal Symptom 
Rating Scale.68 Of note, one study showed that patients 
with SCZ with tardive dyskinesia (TD) had lower plasma 
BDNF levels than those without TD.69 Data on anti-
psychotics dosages will be collected and converted to 
chlorpromazine equivalents for data analysis.
Biometric, metabolic and cardiovascular measures
BDNF appears to regulate appetite and weight regula-
tion. Indeed, BDNF dysregulation has been detected in 
eating disorders, and might be determined via modula-
tion of the serotonin system. In fact, infusion of BDNF in 
the hypothalamus of rats has been shown to increase sero-
tonin turnover and suppress appetite.70 Further support 
for the regulatory role of BDNF in appetite and weight 
through modulation of the serotonin system comes from 
studies showing that mice with only one copy of the 
BDNF gene displayed increased food intake and weight.71 
This corresponded to a decreased serotonin metabolite 
to serotonin ratio. Further, deletion of the BDNF gene 
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leads to similar hyperphagic and obese phenotypes.72 
There is also evidence suggesting that BDNF may regulate 
weight and food intake through the dopamine system.73 74 
In addition, the attentional bias to food cues in low-re-
strained obese or overweight individuals was significantly 
altered by antagonism on dopamine receptors 3.75 Based 
on these findings, we will evaluate the following clin-
ical parameters: weight, waist circumference, body mass 
index, liver and kidney function panel, serum glucose, 
glycosylated haemoglobin, lipid profile, prolactin and 
creatine phosphokinase. The cardiovascular function will 
be monitored by ECG, with evaluation of QTc interval. 
Finally, we will collect information on exercise as this can 
impact on BDNF levels.76
sampling and assessment of BdnF serum levels
Blood samples for each patient will be taken at the same 
time of the day (between 8:00 and 10:00 AM). BDNF 
serum levels will be evaluated using BDNF ELISA Kit 
(Booster Immunoleader Biological Technology Co., 
Ltd., Pleasanton, CA, USA, catalogue no EK0307) 
for the quantitative detection of human BDNF in cell 
culture supernatants, serum and plasma. This kit is 
based on a standard sandwich ELISA technology for 
specific quantifications of natural and recombinant 
human BDNF with a high sensitivity (<2 pg/mL) and 
with no detectable cross-reactivity with other relevant 
proteins. After blood sampling, serum will be allowed 
to clot in a serum separator tube for about 4 hours at 
room temperature. After that, it will be centrifuged at 
approximately 1000× g for 15 min. Supernatant serum 
samples will be collected in small aliquot and stored 
immediately at −20°C for future analysis. Then, samples 
will be processed according to kit protocol and instruc-
tions. Optical density absorbance of each sample will 
be read with a 450 nm filter in a microplate reader 
(Thermo Scientific Multiskan FC, Thermo Fisher Scien-
tific Oy Ratastie 2, Finland) within 30 min after the final 
step of the kit procedure. Data obtained will be anal-
ysed using the Thermo Scientific SkanIt Software V.3.0 
for Multiskan FC.
data analysis plan
Mixed-effects linear regression models (MLRM) will 
be used to analyse longitudinal data.77 78 Specifically, 
we will regress independent variables (both categorical 
and continuous) on BDNF serum levels (dependent 
variable). MLRM allow to model individual change over 
time and appear to be more flexible in terms of repeated 
measures, particularly when the number of observa-
tions per subject is not the same at each time point.77 78 
Further, these models allow generalisation of non-nor-
mally distributed data for independent variables. Our 
analysis plan will consist of the following steps. First, we 
will perform a visual inspection of mean BDNF serum 
levels at each time point using boxplots. This will allow 
checking for normality of BDNF serum levels at each time 
point as well as to identify outliers. Second, MLRM will 
be analysed to assess the longitudinal variation of BDNF 
levels while correcting for age and sex. Finally, indepen-
dent variables will be regressed on BDNF serum levels. 
Covariates will be added to significant models to account 
for possible intercorrelations. All data will be analysed 
using ‘lme4’ package implemented in R.79 Missing data 
for independent variables will be dealt with the ‘ na. 
action’ function implemented in R. The statistical signif-
icance of identified MLRM will be calculated using the 
‘multcomp’ R package. Finally, graphical representation 
of MLRM will be obtained with R packages ‘sJPlot’ and 
‘sjmisc’.
ethics and dissemination
This study protocol was approved by the Univer-
sity of Cagliari Health Agency Ethics Committee 
(NP2016/5491). The study will be conducted in accor-
dance with the principles of good clinical practice in the 
Declaration of Helsinki in compliance with the regula-
tions. Written informed consent will be obtained from 
all eligible participants. Participation to the study will be 
voluntary and patients will be able to withdraw consent 
at any point with no disadvantage to their treatments. A 
psychiatric assessment will establish that patients’ ability 
to consent is not compromised by their psychopatho-
logical status.
We plan to disseminate the results of our study through 
conference presentations and publication in interna-
tional peer-reviewed journals. Access to raw data will be 
available in anonymised form upon request to the corre-
sponding author.
dIscussIon
Schizophreniais characterised by three distinct, but 
to a certain extent intertwined, clusters of symptoms: 
positive, negative and cognitive. Each one of these 
clusters presents with a varying degree of severity and 
with a specific prevalence depending on the stage of 
the illness.80 Patients with stable diagnoses of SCZ and 
SAD have often incomplete remissions (particularly 
from negative symptoms), and not rarely recurrences 
or relapses of positive symptoms, mainly delusions and 
hallucinations.81 Cognitive function, however, appears 
to decline steadily over the course of the illness, 
although most of the magnitude of the differences in 
cognition between patients with SCZ and unaffected 
subjects appear to be modulated by age.81
One key aspect in patients with diagnostically stable 
SCZ and SAD is being able to predict the manifestation of 
these psychopathological exacerbations. Certainly, given 
that fluctuations appear to be more prominent for posi-
tive symptoms and to a lesser extent for negative ones, 
rather than for cognition, researchers have focused on the 
identification of prodromal signs of relapses/recurrences 
using, for instance, home telemonitoring of symptoms 
change via mobile phone-based platforms.82 83 This 
approach has proven effective in reducing the number 
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of relapses and consequent hospitalisations in individuals 
with psychosis.82 83
Our prospective study, LABSP, expands on this 
evidence aiming at monitoring not only the clinical 
signs of patients with SCZ over a 24-month period, 
but, more importantly, assessing the predictive power 
of a well-established biomarker of illness status in 
SCZ (BDNF serum levels), on the clinical trajectory 
of SCZ. We expect to find correlation of BDNF levels 
with longitudinal variation of psychopathology, partic-
ularly concerning positive symptoms. This prospective 
approach, to our knowledge, has not been proposed 
previously in the literature, and might offer novel data 
on serum BDNF as a biomarker of psychopathological 
changes in accurately monitored patients with SCZ. If 
such a correlation will be identified, the joint analysis of 
clinical and BDNF data might explain a larger propor-
tion of psychopathological change than clinical data 
alone.
One additional point of novelty concerns the analysis 
of the impact of psychiatric comorbidity on BDNF levels. 
Indeed, SCZ is not rarely associated with other axis I and 
II disorders that typically affect negatively the course and 
outcome of the disorder.84 However, to our knowledge 
the relationship between serum BDNF levels in SCZ and 
psychiatric comorbidities has not been tested in previous 
work. Although this analysis remains a secondary aim of 
our study, the sample size should allow an adequately 
powered post hoc stratification of our prospective data to 
test this relationship.
The wealth of clinical data we are planning to collect 
with LABSP will also allow testing the moderating influ-
ence of relevant clinical variables, such as for instance, 
family history of SCZ. In fact, it is plausible that recruited 
participants with a positive family history of SCZ, will have 
lower baseline BDNF levels compared with those without 
a family history and a different pattern of association 
between serum BDNF levels and the various clinical inde-
pendent variables.
Limitations
Our study has some limitations inherent to its design. 
First, we will study a population recruited in a tertiary 
clinic specialised in treatment of patients with psychosis, 
possibly limiting ecological validity (ie, generalisability) 
of the results. Second, our power analysis is based on 
previous longitudinal estimates of 1.65 mean variation of 
serum BDNF levels over a 1-year follow-up. Although a 
sample size of 59 might be sufficient to detect a longitu-
dinal variation of this magnitude in BDNF serum levels 
we might not be able to detect association signals of small 
effect size between clinical, treatment and cognitive vari-
ables and BDNF. Thus, we plan to extend our recruitment 
well beyond the number provided by our power analysis. 
Finally, notwithstanding the prospective design, clinical 
(illness duration, DUP) and treatment history prior to 
study entry might impact on findings.
concLusIons
In summary, LABSP will allow the prospective assess-
ment of BDNF serum levels, as well as of key clinical and 
treatment-related measures, in a relatively large cohort 
of patients with SCZ and SAD followed up in a natural-
istic setting. This work will provide useful information 
on the relationship between BDNF serum levels and 
psychopathological changes over time. Changes in BDNF 
peripheral levels might be predictive of the psychopatho-
logical trajectory during the 24-month follow-up, and if 
validated in independent samples, might point to a role 
of BDNF as a biomarker of clinical trajectory in patients 
with psychosis.
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